Severe delta variant COVID-19 in a 28-week infant with response to corticosteroids and remdesivir: a case report

Background: In the context of a global COVID-19 pandemic, there have been a variety of reports about the impact of infection to the fetus and in the immediate newborn period. Many babies appear to have a mild clinical course, but there is limited data about preterm infants. Case Presentation: A 28 w...

Full description

Saved in:
Bibliographic Details
Published inEuropean Journal of Medical Case Reports Vol. 7; no. 3; pp. 52 - 56
Main Authors King, Adam, Hassell, Jack, Gunathilaka, Mastiyage, Storey, Caroline, Graham-Evans, Kate, Kachroo, Rahul
Format Journal Article
LanguageEnglish
Published London Discover Publishing Group 2023
Subjects
Antiviral drugs
Case reports
COVID-19
Disease transmission
Mutation
Newborn babies
Premature babies
Steroids
Online AccessGet full text

Cover

More Information
Summary:Background: In the context of a global COVID-19 pandemic, there have been a variety of reports about the impact of infection to the fetus and in the immediate newborn period. Many babies appear to have a mild clinical course, but there is limited data about preterm infants. Case Presentation: A 28 week male infant was delivered with signs of fetal distress, four days after maternal infection with COVID-19. At this time, the delta variant of the virus predominated. After an initial period of stability, the baby significantly deteriorated in the second week and intensive care was escalated approaching maximal therapy. Given the life-threatening severity of the clinical condition, an off-licence trial of remdesivir was started alongside dexamethasone. With this treatment, the patient made a significant improvement and recovered. Conclusion: This case shows the feasibility of using remdesivir in the very premature neonatal population and seems to have been well tolerated.
ISSN:2520-4998
2520-4998
DOI:10.24911/ejmcr/173-1654097760